TL;DR
Researchers at Semmelweis University describe how sleep disorders, depression, obesity, smoking and other health problems may contribute to persistent symptoms in difficult-to-treat rheumatoid arthritis. They propose using treat-to-target monitoring as an early signal to investigate causes beyond inflammation when pain or fatigue continues.
Persistent pain and fatigue in rheumatoid arthritis may have causes beyond active joint inflammation, according to research from Semmelweis University. In publications in Nature Reviews Rheumatology and The Lancet Rheumatology, researchers describe how conditions such as depression, sleep disorders and obesity may help keep symptoms going, and propose a model to guide earlier, more tailored assessment.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The researchers examined links between difficult-to-treat rheumatoid arthritis and other health problems, including depression, smoking, obesity and sleep problems. They say these factors may do more than accompany the disease: they may contribute to persistent symptoms. The report does not establish that any one factor is responsible for an individual patient’s pain.
Rheumatoid arthritis is a chronic autoimmune disease in which the immune system attacks joints, causing pain, swelling and stiffness. Most patients respond well to treatment, but the researchers cite an estimate that 6% to 28% fall into the difficult-to-treat group because they do not achieve lasting remission despite therapy. The estimate’s population and study period are not specified in the supplied report.
The team describes a cycle in which pain and depression can reduce activity, contribute to weight gain and worsen sleep and mood. Those changes may then intensify pain and make daily activities harder. The researchers propose that when inflammation measures improve but pain or fatigue persists, clinicians should investigate other possible contributors instead of assuming that inflammation alone explains the symptoms.
When Better Inflammation Scores Do Not End Pain
The proposed approach could affect how clinicians respond when a patient’s test results improve but the patient continues to suffer. Under treat-to-target care, doctors regularly track disease activity and adjust medication if inflammation remains above target. The researchers argue that the same monitoring can prompt a broader assessment when inflammation falls but symptoms do not.
That distinction matters because persistent symptoms do not, by themselves, show that rheumatoid arthritis treatment has failed or that inflammation is still driving the pain. The model points clinicians toward considering chronic pain, depression, sleep disorders and obesity as possible contributors. The source says the researchers have seen this approach improve outcomes in difficult-to-treat patients, but provides no figures or study details to quantify the effect.
For patients, a broader assessment may lead to care that addresses more of what is affecting daily life. The research also highlights how pain, mood, sleep and physical activity can interact. These connections are presented as possible mechanisms that can sustain symptoms, not as proof that every patient follows the same cycle.
Products Worth Considering

Garmin Venu X1 GPS Smartwatch, 51 mm, Black

Philips Sonicare 7300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black

Oura Ring 5 Smart Ring, Silver, Size 7
As an affiliate, we earn on qualifying purchases.
How Treat-to-Target Care Fits In
In treat-to-target care, clinicians track measurable indicators of rheumatoid arthritis activity over time. If inflammation is not reduced enough, they may adjust treatment, for example by changing a medication dose or switching drugs. The Semmelweis team proposes using persistent symptoms alongside those measures to help identify when further assessment may be needed.
The publications also build on work defining difficult-to-treat rheumatoid arthritis and related treatment strategies. According to the report, those publications have received more than a thousand citations, and the definition is used internationally in discussions of rheumatoid arthritis and other diseases. Citation totals show research attention; they do not establish that the proposed model improves outcomes in every setting.
“With AI-based pattern recognition, we could identify subgroups among patients, and with the help of these data we could create more effective, almost personalized treatment strategies for them.”
— Dr. Lilla Gunkl-Tóth, PhD student at Semmelweis University and first author
How Well the Model Works in Practice
The supplied report does not provide the studies’ methods, participant numbers or detailed outcome data, so the strength and scale of the reported benefits cannot be assessed from this material alone. It also remains unclear how clinicians should weigh each possible contributor for an individual patient, or how widely the proposed model has been tested in routine care.
The researchers describe depression, sleep disorders, obesity and smoking as factors that may contribute to ongoing symptoms. Their account does not establish that these factors cause persistent pain in every patient, or that addressing them will resolve symptoms. The planned work involving artificial intelligence is a future research direction, with no specific project results or timeline given.
Research Turns Toward AI-Based Grouping
The researchers say they plan to take part in projects using artificial intelligence and pattern recognition to identify patient subgroups and inform more personalized treatment strategies. The report gives no timetable or clinical implementation details. For now, the described model is intended to help doctors decide when persistent pain or fatigue warrants a closer look at factors beyond inflammation.
Key Questions
Why can rheumatoid arthritis pain continue when inflammation is controlled?
Researchers say persistent symptoms may be linked to factors beyond active inflammation, including sleep problems, depression, obesity, smoking and other health conditions. These are possible contributors, and the cause can vary from person to person.
What does difficult-to-treat rheumatoid arthritis mean in this report?
The report uses the term for patients who do not achieve lasting remission despite therapy. It cites an estimate of 6% to 28%, but the supplied material does not specify the estimate’s population or time period.
What should happen if inflammation measures improve but symptoms remain?
The researchers propose that clinicians consider whether other factors may be maintaining pain or fatigue, such as chronic pain, depression or sleep disorders. Treatment decisions depend on individual clinical assessment.
Is AI already being used to personalize rheumatoid arthritis treatment in this research?
No. The team describes AI as a planned research direction to identify patient subgroups. The report does not say that an AI-based treatment system is currently in clinical use.
Source: rss
